CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for New Alliance Biosciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

New Alliance Biosciences, Inc.
110 Founders Mill Ct
Phone: (678) 352-9060p:678 352-9060 Roswell, GA  30075-4988  United States Fax: (626) 405-1041f:626 405-1041
This company is no longer actively traded on any major stock exchange.
Business Summary
New Alliance Biosciences, Inc., formerly Sanguine Corporation, through its subsidiary, SGN LifeSciences, is engaged in discovering, developing and commercializing novel biotechnologies. The company is focused on the development and commercialization of perfluorocarbon based therapeutic oxygen carriers. The Company’s core product, PHER-02, is a perfluorocarbon emulsion. PHER-O2 is made up of perfluoro-decalin, which is a type of perfluorocarbon that is harmless to humans and the atmosphere and was used in Fluosol, purified water and a surfactant to hold the emulsion together. PHER-O2 is ideal for medical indications, such as transportation of pancreas islets for treatment of diabetes, ophthalmic retinal surgery, traumatic brain injury, nuclear magnetic resonance imaging, and treatment of heart attacks.
(Source: PRESS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Thomas C.Drees 82 2/8/2011 6/1/1993
President, Chief Executive Officer, Director FrankMarra 48 2/8/2011 2/8/2011
Director Edward L.Kunkel 63 4/1/1994 4/1/1994

Business Names
Business Name
Sanguine Corporation
Sanguine Life Sciences
SGUI

General Information
Number of Employees: 2 (As of 12/31/2011)
Outstanding Shares: 7,321,822 (As of 9/30/2012)
Shareholders: 567
Stock Exchange: OTC
Federal Tax Id: 954347608
Fax Number: (626) 405-1041


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023